The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL

June 21, 2024

Ibrahim Aldoss, MD, City of Hope Comprehensive Cancer Center, Elias Jabbour, MD, MD Anderson Cancer Center

In Partnership With:

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.